Lactobacillus rhamnosus CCFM1130 and application thereof in relieving and treating gout

A technology of CCFM1130 and Lactobacillus rhamnosus, applied in the field of microbiology, can solve problems such as undiscovered, and achieve the effects of promoting expression, reducing serum uric acid levels, and reducing gout

Active Publication Date: 2021-03-12
JIANGNAN UNIV
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The excretion of uric acid in the human body is mainly through the excretion of the kidneys and intestines. As a uric acid transporter, ABCG2 plays an important role in the intestinal excretion of uric acid. The expression of intestinal ABCG2 is considered to be a new target for the treatment of hyperuricemia and gout. point, but currently no drugs targeting intestinal ABCG2 have been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus rhamnosus CCFM1130 and application thereof in relieving and treating gout
  • Lactobacillus rhamnosus CCFM1130 and application thereof in relieving and treating gout
  • Lactobacillus rhamnosus CCFM1130 and application thereof in relieving and treating gout

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Screening of Lactobacillus rhamnosus CCFM1130

[0050] (1) Isolation and screening of Lactobacillus

[0051] (1) Take 1g of fresh feces of healthy adults. After gradient dilution, apply it to LBS medium with 1% nystatin, and place it in a constant temperature incubator at 37°C for 48 hours.

[0052] (2) After cultivation, according to the color, size, and edge shape of the colony, use an inoculation loop to pick up the colony and streak it for purification.

[0053] (3) The obtained colonies were subjected to Gram staining and catalase analysis.

[0054] (4) Retain Gram-positive bacilli and catalase-negative bacteria.

[0055] (2) Molecular biological identification of Lactobacillus

[0056] (1) Single bacterial genome extraction

[0057] (A) cultivating the lactobacilli screened in step (1) overnight;

[0058] (B) Take 1 mL of the bacterial suspension cultivated overnight in a 1.5 mL centrifuge tube, centrifuge at 10000 r / min for 2 min, discard the supern...

Embodiment 2

[0074] Example 2: Detection of tolerance of Lactobacillus rhamnosus CCFM1130 to simulated gastrointestinal fluid

[0075] The cryopreserved Lactobacillus rhamnosus CCFM1130 was inoculated in the MRS medium, cultured at 37°C for 14 hours, and then subcultured in the MRS medium for 2 to 3 times.

[0076] Take 3mL of the culture solution of Lactobacillus rhamnosus CCFM1130 and centrifuge at 8000×g for 2min to collect the bacteria, mix it with 3mL pH 3.0 artificial simulated gastric juice (containing 3g / L pepsin, pH=3.0 physiological saline), and incubate at 37°C. Cultivate, take samples at 0h and 2h respectively, use MRS agar medium to pour culture, count the colonies on the plate, determine the number of viable bacteria and calculate their survival rate.

[0077] Take 3 mL of the culture solution of Lactobacillus rhamnosus CCFM1130 and centrifuge at 8000×g for 2 min to collect the cells, add 3 mL of pH8.0 artificial simulated intestinal fluid (physiological saline containing 1 g...

Embodiment 3

[0081] Example 3: Lactobacillus rhamnosus CCFM1130 has no toxic side effects on KunMing mice

[0082] Suspend Lactobacillus rhamnosus CCFM1130 in 100g / L skim milk solution to make a concentration of 4.0×10 9 CFU / mL bacterial suspension. Twelve healthy male KunMing mice with a body weight of about 24-32 g were taken, and after one week of adaptation to the environment, they were divided into CCFM1130 group and control group. The CCFM1130 group was intragastrically administered 0.3 mL of the bacterial suspension at this concentration once a day, and the control group was intragastrically administered the same volume of 100 g / L skim milk solution without Lactobacillus rhamnosus CCFM1130, observed for one week, and recorded death and body weight.

[0083] The results of these tests are listed in Table 2. The results showed that feeding concentration 1×10 9 CFU / Lactobacillus rhamnosus CCFM1130 had no significant impact on mice, no significant change in body weight, and no death....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses lactobacillus rhamnosus CCFM1130 and application thereof in relieving and treating gout, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CCFM1130 disclosed by the invention can be used for reducing the serum uric acid level of a hyperuricemia mouse, inhibiting the xanthine oxidase (XOD) activity of serum and a liver, reducing the occurrenceof hyperuricemia and gout, down-regulating serum blood sugar, serum total triglyceride (TG), and serum total cholesterol (TC) level, and inhibiting serum alkaline phosphatase (ALP) activity; and theexpression of the ileum uric acid transport protein ABCG2 is promoted. The lactobacillus rhamnosus CCFM1130 disclosed by the invention can tolerate the gastrointestinal tract environment, can be usedfor preparing functional microbial inoculants, foods and medicines capable of alleviating hyperuricemia and gout and capable of being taken into gastrointestinal tracts, and has a wide application prospect.

Description

technical field [0001] The invention relates to Lactobacillus rhamnosus CCFM1130 and its application in alleviating and treating gout, and belongs to the technical field of microorganisms. Background technique [0002] Hyperuricemia (Hyperuricemia, HUA) refers to a disease in which the level of uric acid in the blood exceeds the normal value. In recent years, with the improvement of living standards, the incidence of hyperuricemia is also increasing. In my country, patients with hyperuricemia account for about 13.3% of the total population. Urate stones caused by long-term hyperuricemia can further induce gout. At the same time, hyperuricemia is considered a risk factor for cardiovascular and cerebrovascular diseases, chronic kidney disease, and atherosclerosis, which seriously endangers human health. Therefore, the treatment of hyperuricemia has attracted great attention. At present, the drugs for the treatment of hyperuricemia mainly include allopurinol (xanthine oxidase...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N1/20A61K35/747A61P19/06A23L33/135C12R1/225
CPCC12N1/20A61K35/747A61P19/06A23L33/135A23V2002/00A23V2400/175A23V2200/30A23V2200/328A23V2200/3262Y02A50/30
Inventor 王刚倪彩新王琳琳翟齐啸陆文伟崔树茂杨波毛丙永唐鑫赵建新张灏陈卫
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap